Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines
The Journal of Clinical Endocrinology & Metabolism · 17.05.2024 · 109 (6) · 1630-1655
DOI: 10.1210/clinem/dgad762 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 02.01.2024. Verfasst von Victoria Fitz und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114, US…. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Inositol. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian National Health and Medical Research Council, NHMRC, Centre for Research Excellence in Women's Health in Reproductive Life.
Abstract (Originalsprache)
Context
Insulin resistance is common in women with polycystic ovary syndrome (PCOS). Inositol may have insulin sensitizing effects; however, its efficacy in the management of PCOS remains indeterminate.
Objective
To inform the 2023 international evidence-based guidelines in PCOS, this systematic review and meta-analysis evaluated the efficacy of inositol, alone or in combination with other therapies, in the management of PCOS. Data Sources Medline, PsycInfo, EMBASE, All EBM, and CINAHL from inception until August 2022. Study Selection Thirty trials (n = 2230; 1093 intervention, 1137 control), with 19 pooled in meta-analyses were included. Data Extraction Data were extracted for hormonal, metabolic, lipids, psychological, anthropometric, reproductive outcomes, and adverse effects by 1 reviewer, independently verified by a second. Data Synthesis Thirteen comparisons were assessed, with 3 in meta-analyses. Evidence suggests benefits for myo-inositol or D-chiro-inositol (DCI) for some metabolic measures and potential benefits from DCI for ovulation, but inositol may have no effect on other outcomes. Metformin may improve waist-hip ratio and hirsutism compared to inositol, but there is likely no difference for reproductive outcomes, and the evidence is very uncertain for body mass indexI. Myo-inositol likely causes fewer gastrointestinal adverse events compared with metformin; however, these are typically mild and self-limited.
Conclusion
The evidence supporting the use of inositol in the management of PCOS is limited and inconclusive. Clinicians and their patients should consider the uncertainty of the evidence together with individual values and preferences when engaging in shared decision-making regarding the use of inositol for PCOS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114, USA.
- School of Health and Society, Faculty of Education, Health and Wellbeing, University of Wolverhampton, Wolverhampton WV1 1LY, UK.
- NICM Health Research Institute, Western Sydney University, Penrith 2751, Australia.
- Primary Care Research Centre, University of Southampton, Southampton SO17 1BJ, UK.
- UPMC Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA 15260, USA.
- Discipline of Paediatrics, The University of Adelaide and Robinson Research Institute, Adelaide 5005, Australia.
ORCID-Profile: Rong Li, Aya Mousa, Helena Teede, Carolyn Ee
Förderung
- Australian National Health and Medical Research Council
- NHMRC
- Centre for Research Excellence in Women's Health in Reproductive Life
- CRE WHIRL
- NHMRC CRE WHIRL
- Centre for Research Excellence in Women’s Health in Reproductive Life
Zitieren
APA
Fitz, V., Graca, S., Mahalingaiah, S., Liu, J., Lai, L., Butt, A., Armour, M., Rao, V., Naidoo, D., Maunder, A., Yang, G., Vaddiparthi, V., Witchel, S. F., Pena, A., Spritzer, P. M., Li, R., Tay, C., Mousa, A., Teede, H., & Ee, C. (2024). Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. The Journal of Clinical Endocrinology & Metabolism, 109(6), 1630-1655. https://doi.org/10.1210/clinem/dgad762
Vancouver
Fitz V, Graca S, Mahalingaiah S, Liu J, Lai L, Butt A, et al. Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. The Journal of Clinical Endocrinology & Metabolism. 2024;109(6):1630-1655. doi:10.1210/clinem/dgad762
BibTeX
@article{Fitz2024,
author = {Fitz, Victoria and Graca, Sandro and Mahalingaiah, Shruthi and Liu, Jing and Lai, Lily and Butt, Ali and Armour, Mike and Rao, Vibhuti and Naidoo, Dhevaksha and Maunder, Alison and Yang, Guoyan and Vaddiparthi, Vaishnavi and Witchel, Selma F and Pena, Alexia and Spritzer, Poli Mara and Li, Rong and Tay, Chau and Mousa, Aya and Teede, Helena and Ee, Carolyn},
title = {Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
volume = {109},
number = {6},
pages = {1630--1655},
doi = {10.1210/clinem/dgad762}
}
EUVIMED